TB/Flu-06E
The vaccine platform is based on the live influenza virus vector that is highly attenuated through alteration in NS1 protein function. This effect is achieved by the replacement of immunosuppressive C-terminal part of NS1 open reading frame with foreign sequences, encoding ESAT-6 antigen of M. tuberculosis. Importantly, viral vector itself acts as an adjuvant, stimulating…
Read MoreALHA
Ag85A-LpqH (AL) is a recombinant subunit vaccine that combines the T cell-stimulating antigen Ag85A with the humoral immunity-targeting antigen LpqH. It is constructed using the pET-21a(+) vector, expressed in E. coli BL21(DE3), and formulated with aluminum for subcutaneous administration.
Read MoreChAdOx1.85A+MVA85A*
ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A. The target route of administration for ChAdOx1.85A is aerosol, and intramuscular for MVA85A.
Read MoreVPM1002
VPM1002 is a recombinant, urease C-deficient, listeriolysin expressing BCG vaccine strain and was generated in order to induce a broader immune response against mycobacterial antigens.
Read MoreRUTI®
RUTI® is a liposome suspension of the drug substance with a charge excipient. The drug substance is based on cell wall nanofragments of Mycobacterium tuberculosis. It contains a wide mixture of antigens obtained by a M. tuberculosis growth under stress conditions.
Read More